ADC Therapeutics SA (ADCT) ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
ADC Therapeutics S.A. NYSE:ADCT Healthcare · Biotechnology
CLOSED · Nov 3 $1.55 CLOSED · Nov 3 Prev close $1.54 Close $1.55 0.00% AH close $1.55 VOL 866K $ Vol $1.36M RVOL 0.56x
Mkt Cap $197.88M
VOL 866K sh
$ Vol $1.36M
RVOL 0.56×
Press Release
ADC Therapeutics to Present at November Investor Conferences
ADC Therapeutics announced CEO Ameet Mallik will present fireside chats at the Guggenheim Healthcare Innovation Conference on November 10 and the Jefferies Global Healthcare Conference on November 19.
Webcasts will be available on the company's investor relations site, with replays for roughly 30 days.
The release contains no new business, clinical, or financial developments; it is a scheduling notice.
• 13h ago AI analysis › Press Release
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics granted a new employee inducement options to purchase 17,000 common shares on November 2, 2026, disclosed under NYSE Rule 303A.08.
The grant was approved by the Compensation Committee under the company's Inducement Plan and vests over four years, subject to continued employment.
The disclosure is routine boilerplate with no bearing on the company's financial position or ZYNLONTA commercialization.
• 1d ago AI analysis › Press Release
ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026
ADC Therapeutics will report third quarter 2026 financial results via press release on Monday, November 9, 2026.
The company is a commercial-stage antibody drug conjugate developer whose marketed product is ZYNLONTA, approved for relapsed or refractory diffuse large B-cell lymphoma.
This is a scheduling notice only; no financial figures or new developments were disclosed.
• 1d ago AI analysis › Press Release ⚠ 2
ADC Therapeutics Announces ZYNLONTA® Updates in Japan
ADC Therapeutics' Japanese licensing partner Tanabe Pharma filed a marketing authorization application with Japan's Ministry of Health, Labor and Welfare for ZYNLONTA in relapsed or refractory DLBCL after two or more lines of systemic therapy.
The filing is based on a Phase 1/2 Japanese bridging study showing a 58.1% overall response rate and 41.9% complete response rate, consistent with the pivotal global LOTIS-2 study with no new safety concerns.
Tanabe Pharma also sublicensed Japanese commercialization rights to Nippon Shinyaku, an established oncology commercial player. The filing acceptance and first commercial sale in Japan represent near-term milestone payments to ADC Therapeutics under the 2022 license agreement.
• 5d ago AI analysis › Press Release ● Major ⚠ 5
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics announced a comprehensive financial restructuring: an $86.6 million private placement, an amended HealthCare Royalty agreement, and a refinanced senior secured term loan reduced to $50 million.
The PIPE, anchored by new investor Bain Capital Life Sciences plus existing holders Redmile, TCGX and Nantahala, sells 12.9 million shares at $1.42 and pre-funded warrants on 48.1 million shares at $1.32, with net proceeds of roughly $76.3 million expected.
The HCR amendment eliminates a $150 million change-of-control payment and the loan amendment removes the minimum liquidity covenant, extending the expected cash runway into 2029. Pro forma, the company would have had about $196 million in cash as of September 30, 2026.
The relief comes at a heavy dilution cost: lender warrants were repriced from $8.30 to $1.00 and HCR warrants from $3.8130 to $0.10, and the company disclosed preliminary Q3 ZYNLONTA revenue of about $21 million.
• 26d ago AI analysis › Press Release ⚠ 3
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
ADC Therapeutics CEO Ameet Mallik will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York on Friday, September 11, 2026, at 9:10 a.m. ET.
A live webcast will be available via the Events & Presentations page of the company's investor relations site, with a replay accessible for approximately 30 days.
The release contains no new financial or clinical data, though its forward-looking statements reiterate FDA 'serious concerns' raised at a recent pre-sBLA meeting over the LOTIS-5 trial results and a cash runway into at least 2028 that assumes drawing to the minimum liquidity level required under loan covenants.
• 2mo ago AI analysis › Press Release ● Major ⚠ 3
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
ADC Therapeutics reported Q2 2026 total revenue of $19.2 million and narrowed its net loss to $16.6 million, or $0.11 per share, helped by a 17% workforce reduction and operational efficiencies that are expected to generate $10 million in annualized savings.
However, the company faces a major regulatory hurdle after the FDA noted substantial concerns regarding the benefit-risk profile of the LOTIS-5 confirmatory trial, citing an imbalance in Grade 5 events relative to the marginal treatment benefit, leaving the path to full approval uncertain.
Management is shifting strategic focus toward the LOTIS-7 combination of ZYNLONTA plus glofitamab, which completed enrollment and demonstrated compelling safety data, with plans to submit for Breakthrough Therapy Designation and initiate a Phase 3 trial.
• 2mo ago AI analysis › Press Release
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
ADC Therapeutics announced it will host a conference call on August 13, 2026, at 8:30 a.m. EDT to report its second quarter 2026 financial results and provide operational updates.
The event will be accessible via live webcast on the company's investor relations website and through a toll-free dial-in number for North American participants.
The company is a commercial-stage biotechnology firm focused on antibody drug conjugates, with its lead product being ZYNLONTA for relapsed or refractory diffuse large B-cell lymphoma.
• 2mo ago AI analysis › Press Release
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics granted an employee options to purchase 17,000 common shares as a hiring inducement, effective July 1, 2026.
The award vests in 25% increments on the first anniversary and monthly thereafter, fully vesting by the fourth anniversary.
The grant was made under the company's Inducement Plan pursuant to NYSE Listed Company Manual Rule 303A.08.
• 4mo ago AI analysis › Press Release
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
ADC Therapeutics completed enrollment in the LOTIS-7 Phase 1b trial evaluating ZYNLONTA plus glofitamab in relapsed or refractory diffuse large B-cell lymphoma.
The study treated 100 patients at a 150 µg/kg dose, with preliminary data showing an 89.8% overall response rate and 77.6% complete response rate in 49 evaluable patients.
Full data readout is expected in the fourth quarter of 2026, and the company plans to assess potential regulatory and compendia pathways for the combination.
• 4mo ago AI analysis › Press Release ⚠ 2
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
ADC Therapeutics is implementing a strategic reorganization that includes a 17% global workforce reduction to extend its cash runway into 2028 and generate approximately $10 million in annualized savings.
The restructuring aligns resources behind the ZYNLONTA franchise, supporting a planned pre-sBLA meeting with the FDA in August 2026 and a subsequent sBLA submission in the fourth quarter for the LOTIS-5 trial.
The company expects to incur one-time pre-tax charges of roughly $3 million related to severance and benefits, primarily in the second quarter of 2026.
• 4mo ago AI analysis › Press Release ● Major ⚠ 4
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics reported positive topline data from the Phase 3 LOTIS-5 trial, where ZYNLONTA plus rituximab met the primary endpoint of progression-free survival (HR 0.73, p=0.008) versus R-GemOx in relapsed/refractory DLBCL.
The combination also showed superior complete response rates (39.5% vs 26.7%) and duration of response, with no detrimental effect on overall survival (HR 0.96).
However, the test arm had higher rates of serious adverse events (49.0% vs 34.5%) and Grade 5 TEAEs (13.2% vs 4.6%), particularly in patients aged 75+, which the company will discuss with the FDA ahead of a planned sBLA filing in Q4 2026.
• 5mo ago AI analysis › Press Release ⚠ 1
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
ADC Therapeutics reported first quarter 2026 net product revenue of $20.0 million, up from $17.4 million in the prior year, driven by higher volume and pricing.
The company expects to announce topline results from the pivotal LOTIS-5 Phase 3 trial in the second quarter of 2026, with full data from both LOTIS-5 and LOTIS-7 anticipated by year-end.
Cash and cash equivalents were $231.0 million as of March 31, 2026, providing an expected cash runway at least into 2028 to fund operations and upcoming milestones.
• 6mo ago AI analysis › Press Release
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
prnewswire.com • 6mo ago Press Release
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
ADC Therapeutics announced it will host a conference call on May 4, 2026, to report first-quarter 2026 financial results and provide operational updates.
The call is scheduled for 8:30 a.m. EDT and will be accessible via webcast and dial-in.
The company is a commercial-stage biotech firm focused on antibody drug conjugates, with ZYNLONTA as its lead product.
• 6mo ago AI analysis › Press Release
ADC Therapeutics Announces New Employee Inducement Grant
prnewswire.com • 7mo ago 
